Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Tesaro target lowered to $164 at Wedbush after Lynparza demonstrates similar top-line efficacy in maintenance therapy SOLO-2 study (153.65)Wedbush lowers their TSRO tgt to $164 from $200. AZN's SOLO-2 results surpassed their expectations, demonstrating similar top-line efficacy for Lynparza as that achieved by niraparib in the NOVA study. They see the investigator-assessed PFS as the more relevant comparison given this more closely matches the NOVA study assessment protocol, but have reduced their market share expectations for niraparib in the gBRCA setting to account for expected competition. However, they estimate niraparib gaining a competitive market share in the gBRCAmut maintenance setting, given first-to-market and dosing advantages.</td> </tr></table>"